Zusammenfassung
Die frühzeitige Diagnose eines gastrointestinalen Tumors kann zu einer Reduktion der Mortalität und zu einer Verbesserung der Prognose führen. Die Effektivität der Screeningprogramme ist für das kolorektale Karzinom belegt. Entsprechende Algorithmen haben sich durchgesetzt. Bei anderen Tumoren bleibt die abschließende Beurteilung von Screeningmaßnahmen z. T. unbeantwortet. Inzidenz der Erkrankung, Kosten der Maßnahmen und das Risiko einer sog. Überdiagnose müssen dabei gegeneinander abgewogen werden.
Abstract
Early diagnosis of gastrointestinal tumors may lead to a reduction in mortality and to improved prognosis. The effectiveness of screening programs for colorectal cancer has been proven. Corresponding algorithms have prevailed. For other tumors the final judgment of screening programs remains mainly unanswered. The incidence of the disease, costs of screening and the risk of overdiagnosis still need to be evaluated.
Literatur
Adler A, Wegscheider K, Lieberman D et al (2012) Factors determining the quality of screening colonoscopy: a prospective study on adenomadetection rates, from 12,134 examinations (Berlin colonoscopy project 3, BECOP-3). Gut (Epub ahead of print)
Brenner H, Altenhofen L, Katalinic A et al (2011) Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol 174: 1140–1146
Cao Q, Ran ZH, Xiao SD (2007) Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 8: 15–22
Diamond SJ, Enestvedt BK, Jiang Z et al (2011) Adenoma detection rate increases with each decade of life after 50 years of age Gastroint Endosc 74: 135–140
Fietkau R, Zettl H, Klöcking S, Kundt G (2004) Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry. Strahlenther Onkol 180: 478–487
Hoffmeister M, Haug U, Brenner H (2009) Screening: prerequisites. Internist 49: 655–659
Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365: 1375–1383
Jorgensen OD, Kronborg O, Fenger C (2002) A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50: 29–32
Kewenter J, Brevinge H, Engarås B et al (1994) Results of screening, rescreening and follow-up in a prospective randomized study for detection of colorectal cancer by fecal-occult-blood testing. Results for 68,308 subjects. Scand J Gastroenterol 29: 468–473
Kumon RE, Repaka A, Atkinson M et al (2012) Characterization of the pancreas in vivo using EUS spectrum analysis with electronic array echoendoscopes. Gastrointest Endosc 75: 1175–1183
Mandel JS, Bond JH, Church TR et al (1993) Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–1371
Pickhardt PJ, Choi JR, Hwang I et al (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349: 2191–2200
Quintero E, Castells A, Bujanda L et al (2012) Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366: 697–706
Raimondi S, Lowenfels AB, Morselli-Labate AM et al (2010) Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24: 349–358
Riemann JF, Maar C, Betzler M et al (2011) Early detection of colonic cancer in the National Cancer Program–present status and recommendations Z Gastroenterol 49: 1428–1431
Sarkar M, Stewart S, Yu A et al (2012) Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 19: 594–600
Schneider R, Slater EP, Sina M et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10: 323–330
Sieg A, Theilmeier A (2006) Ergebnisse der Vorsorge-Koloskopie 2005. Dtsch Med Wochenschr 131: 379-383
Spada C, Hassan C, Galmiche JP et al (2012) Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 44: 527–536
Uemura N, Okamoto S, Yamamoto S et al (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789
Van Rossum LG, van Rijn AF, Laheij RJ et al (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135: 82–90
Warren J, Xiong W, Bunker A et al (2011) Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer BMC 14: 129–133
Watabe H, Mitsushima T, Yamaji Y et al (2005) Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54: 764–768
Winawer SJ, Zauber AG, Ho MN et al (1993) Reduction of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 29: 1977–1981
Zauber AG, Winawer SJ, O’Brien MJ et al (2012) Polypectomy and long-term prevention of colorectal-cancer deaths N Engl J Med 366: 687–696
Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417–421
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Damian, U., Schilling, D. & Riemann, J. Vorsorge gastrointestinaler Tumoren. Gastroenterologe 7, 531–540 (2012). https://doi.org/10.1007/s11377-012-0704-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-012-0704-8